PRE-FUNDED COMMON STOCK PURCHASE WARRANT INTEC PARENT, Inc.Intec Parent Inc. • July 29th, 2021 • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Intec Parent, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.01 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 29th, 2021 • Intec Parent Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July 23, 2021, between Intec Parent, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • July 29th, 2021 • Intec Parent Inc. • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 23, 2021, by and between Intec Parent, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
PURCHASE AGREEMENTPurchase Agreement • December 23rd, 2022 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS PURCHASE AGREEMENT (the “Agreement”), dated as of December 22, 2022, is made by and between INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
STRICTLY CONFIDENTIAL Intec Pharma Ltd.Letter Agreement • July 29th, 2021 • Intec Parent Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • December 23rd, 2022 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 22, 2022, is entered into by and between INDAPTUS THERAPEUTICS, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).
AT THE MARKET OFFERING AGREEMENT June 1, 2022Terms Agreement • September 1st, 2022 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • New York
Indaptus Therapeutics, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows:
EMPLOYMENT AGREEMENTEmployment Agreement • March 13th, 2024 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), effective as of August 7, 2023 (the “Effective Date”), is between Indaptus Therapeutics, Inc. (the “Company”) and Roger J. Waltzman (the “Executive”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 8th, 2024 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 7, 2024, between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • August 6th, 2021 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AGREEMENT (the “Agreement”) is made and entered into as of this ___ day of _______________ between Indaptus Therapeutics, Inc., a Delaware corporation (“the Company”, which term shall include where appropriate any Enterprise (as hereafter defined) controlled directly or indirectly by the Company and any successor to the Company), and [__________] (“Indemnitee”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 6th, 2021 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • New York
This Employment Agreement (this “Agreement”), effective as of August 4, 2021 (the “Effective Date”), is between Indaptus Therapeutics, Inc. (the “Company”) and Jeffrey A. Meckler (the “Executive”).
First Amendment to Ordinary Shares Purchase AgreementShares Purchase Agreement • June 28th, 2021 • Intec Parent Inc. • Pharmaceutical preparations
This First Amendment to the Ordinary Shares Purchase Agreement (the “First Amendment”) is made and entered into as of the 16th day of May, 2021 (the “First Amendment Effective Date”) by and between INTEC PHARMA LTD., a company organized and existing under the laws of the State of Israel (the “Company”), and ASPIRE CAPITAL FUND, LLC, an Illinois limited liability company (the “Buyer”).
ContractIndaptus Therapeutics, Inc. • September 1st, 2022 • Pharmaceutical preparations
SERVICES AGREEMENTServices Agreement • August 6th, 2021 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations • New York
This SERVICES AGREEMENT (this “Agreement”) is made and entered as of August 4, 2021, by and between Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”) and Nir Sassi of Rothschild 69b Kadima, Israel (the “Service Provider”) (The Company and the Service Provider shall additionally be referred as each, a “Party” and collectively, the “Parties”).
EMPLOYMENT AGREEMENTEmployment Agreement • March 21st, 2022 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations
This Employment Agreement (this “Agreement”), effective as of January 1, 2022 (the “Effective Date”), is between Intec Pharma Ltd. an Israeli company number 51-3022780 (the “Company”), the wholly-owned subsidiary of Indaptus Therapeutics, Inc. (the “Indaptus”) and Nir Sassi, ID [***] whose address is [***] (the “Executive”).
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ON TRANSFER SET FORTH IN SECTION 5 OF THIS WARRANTIndaptus Therapeutics, Inc. • August 8th, 2024 • Pharmaceutical preparations • New York
Indaptus Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that [●], or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after August 8, 2024 (the “Initial Exercise Date”) and on or before 5:00 p.m. (New York City time) on August 8, 2029 (the “Termination Date”), [●] shares of Common Stock, $0.01 par value per share, of the Company (“Common Stock”), at a purchase price of $1.70 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively. This Warrant is one of the Common Stock Purchase Warrants (the “Warrants”) issued pursuant to that certain Securities Purchase Agreement, dated as of August 7, 2024,
PLACEMENT AGENT AGREEMENTPlacement Agent Agreement • August 8th, 2024 • Indaptus Therapeutics, Inc. • Pharmaceutical preparations
This Placement Agent Agreement (“Agreement”) is made by and between Indaptus Therapeutics, Inc, (the “Company”), and Paulson Investment Company, LLC, a Delaware limited liability company (the “Placement Agent”), as of the date first above written. The Company hereby engages the Placement Agent to assist the Company as its exclusive placement agent in arranging a placement of its equity securities (the “Securities”), on terms to be determined by the parties hereto (the “Offering”). The terms of the Offering will be more fully described in the definitive transaction documents pertaining to the Offering, to be prepared by the Company.
